GlassScriptPhysician profile
Asha Inniss
NPI 1730634742
$3,455.26
in general payments reported to CMS, 2019-2025
35 companies · $38.65 in 2025
The $38.65 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.84 · 2022: $217 · 2023: $938 · 2024: $2,237 · 2025: $38.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,156.19 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.79 | 2022-2025 | |
| Abbott Laboratories | $284.02 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $244.56 | 2023-2024 | |
| Lilly USA, LLC | $243.26 | 2023-2024 | Emgality, Amyvid, Reyvow |
| Emd Serono, INC. | $229.01 | 2024 | |
| Ucb, INC. | $219.92 | 2023-2024 | Rystiggo, Briviact |
| Biogen, INC. | $203.45 | 2023-2024 | Vumerity, Tysabri, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $194.69 | 2023-2024 | Ajovy, Austedo Xr |
| Sk Life Science, INC. | $178.98 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $140.21 | 2023-2024 | Acthar |
| Harmony Biosciences LLC | $111.57 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $102.94 | 2022-2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $102.84 | 2023-2024 | Ultomiris |
| Argenx US, INC. | $72.07 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $66.70 | 2023-2024 | Hyqvia, Gammagard |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $60.31 | 2023-2024 | |
| Amgen INC. | $54.21 | 2023-2024 | Uplizna, Aimovig |
| Octapharma USA, INC. | $50.10 | 2023-2024 | Panzyga |
| Grifols USA, LLC | $46.06 | 2024 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $45.14 | 2024 | Ongentys 50mg Capsules 30, Rytary |
| Neurelis, INC. | $41.09 | 2023 | Valtoco |
| Novartis Pharmaceuticals Corporation | $40.96 | 2023-2024 | |
| Csl Behring | $32.34 | 2024 | Hizentra |
| Aucta Pharmaceuticals, INC. | $31.64 | 2024 | Motpoly Xr |
| Eisai INC. | $27.75 | 2024 | |
| Axsome Therapeutics, INC. | $23.69 | 2024 | Sunosi |
| Neurocrine Biosciences, INC. | $22.00 | 2024 | Ingrezza |
| Kyowa Kirin, INC. | $21.36 | 2023 | Nourianz |
| Ge Healthcare | $20.83 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $20.27 | 2024 | Lumryz |
| Ultragenyx Pharmaceutical INC. | $17.44 | 2023 | |
| Acorda Therapeutics, INC | $17.13 | 2023 | Inbrija |
| Livanova USA, INC. | $16.85 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals INC. | $16.54 | 2023 | Trudhesa |
| Lundbeck LLC | $14.54 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Inniss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.